CenExel ACT
Anaheim, California, 92801, United States
NCT Number: NCT06964776
The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Anaheim, California, 92801, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administered orally
Administered placebo
Administered orally
Time frame: Day 1 to Day 17
Time frame: Day 1 to Day 17
Time frame: Baseline to Study Completion (Up to Day 17)
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
Time frame: Baseline to Study Completion (Up to Period 4, Day 4)
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
Time frame: Day 1 to Day 13
Time frame: Day 1 to Day 13
Time frame: Day 1 to Day 17
PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989
Time frame: Day 3 and Day 11
PK of midazolam and 1'-hydroxymidazolam (AUC), where midazolam is administered alone and in the presence of LY4268989
Time frame: Day 1 to Day 17
PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989
Time frame: Day 3 to Day 11
PK of midazolam and 1'-hydroxymidazolam (Cmax), when midazolam is administered alone and in the presence of LY4268989
Time frame: Day 1 to Day 7
Time frame: Day 1 to Day 7
Time frame: Day 1 to Day 12
Time frame: Day 1 to Day 12
Time frame: Day 1 to Day 4
Time frame: Day 1 to Day 4
Time frame: Time Frame: Day 6 to Day 15
Time frame: Time Frame: Day 6 to Day 15
Time frame: Time Frame: Day 3 and Day 10
Time frame: Time Frame: Day 3 and Day 10
Eli Lilly and Company
Industry
A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06840925
Healthy
Melbourne, Victoria, Australia
View Trial DetailsNCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT05370222
Behavior, Behavior, Animal
Clermont-Ferrand, AURA, France
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial Details